Mike Mensinger Sells 1,064 Shares of Beta Bionics (NASDAQ:BBNX) Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mike Mensinger sold 1,064 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $12.36, for a total value of $13,151.04. Following the sale, the insider owned 188,793 shares in the company, valued at approximately $2,333,481.48. This represents a 0.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Mike Mensinger also recently made the following trade(s):

• On Tuesday, January 6th, Mike Mensinger sold 2,200 shares of Beta Bionics stock. The shares were sold at an average price of $30.10, for a total value of $66,220.00.
• On Friday, January 2nd, Mike Mensinger sold 7,800 shares of Beta Bionics stock. The shares were sold at an average price of $29.61, for a total value of $230,958.00.

Beta Bionics Stock Down 1.6%

Shares of NASDAQ BBNX opened at $11.38 on Thursday. The company has a market cap of $505.04 million, a P/E ratio of -5.84 and a beta of 5.60. Beta Bionics, Inc. has a 52 week low of $8.89 and a 52 week high of $32.71. The business has a 50-day simple moving average of $18.35 and a two-hundred day simple moving average of $22.35.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings results on Tuesday, February 17th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.12. The firm had revenue of $32.12 million for the quarter. Beta Bionics had a negative net margin of 73.02% and a negative return on equity of 20.29%.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on BBNX shares. UBS Group raised Beta Bionics to a “strong-buy” rating in a report on Monday, February 9th. Stifel Nicolaus cut their price target on shares of Beta Bionics from $25.00 to $22.00 and set a “buy” rating for the company in a research report on Wednesday, February 18th. TD Cowen initiated coverage on Beta Bionics in a research note on Monday, January 26th. They set a “hold” rating and a $17.00 price objective for the company. Bank of America cut Beta Bionics from a “buy” rating to a “neutral” rating in a research note on Friday, January 9th. Finally, Lake Street Capital set a $20.00 price objective on shares of Beta Bionics in a research report on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $23.20.

Institutional Investors Weigh In On Beta Bionics

Hedge funds have recently added to or reduced their stakes in the stock. GPS Wealth Strategies Group LLC increased its stake in shares of Beta Bionics by 45.0% in the 3rd quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock worth $29,000 after purchasing an additional 450 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Beta Bionics by 0.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 331,623 shares of the company’s stock worth $10,105,000 after buying an additional 931 shares in the last quarter. Deutsche Bank AG lifted its stake in Beta Bionics by 3.4% in the 4th quarter. Deutsche Bank AG now owns 39,300 shares of the company’s stock worth $1,197,000 after purchasing an additional 1,296 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in Beta Bionics by 203.6% during the third quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock valued at $47,000 after buying an additional 1,594 shares during the last quarter. Finally, Summit Securities Group LLC purchased a new position in shares of Beta Bionics in the fourth quarter valued at $52,000.

Beta Bionics News Roundup

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Recent operational/analyst context supports longer‑term upside — Beta Bionics beat EPS estimates in its Feb. 17 quarter and the consensus analyst view remains a “Moderate Buy” with a $23.20 average price target, providing a counterbalance to near‑term selling. MarketBeat coverage
• Neutral Sentiment: Short‑interest data published for early March shows implausible values (entries report “0 shares”/NaN and 0.0 days to cover), so there is no reliable signal from short sellers — treat reported short‑interest changes as inconclusive until corrected by exchanges or data providers.
• Negative Sentiment: A wave of small insider sell orders was disclosed in early March (including the CFO’s sale of 1,428 shares and several other executive sales at roughly $12.36 each). Multiple Form 4 filings and press coverage frame this as coordinated executive selling, which often pressures sentiment for small‑cap biotech/medical device stocks. TipRanks: Insiders Cash Out
• Negative Sentiment: A securities‑litigation firm (Faruqi & Faruqi, LLP) issued a shareholder reminder/investigation notice seeking investors who experienced losses, increasing legal and reputational risk and likely weighing on near‑term sentiment until the matter is clarified. GlobeNewswire: Faruqi & Faruqi notice

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.